

**Chapter 11**  
**Bibliography**

Abdo, S., Shi, Y., Otoukesh, A., Ghosh, A., Lo, C.-S., Chenier, I., Filep, J.G., Ingelfinger, J.R., Zhang, S.L., Chan, J.S.D., 2014. Catalase overexpression prevents nuclear factor erythroid 2-related factor 2 stimulation of renal angiotensinogen gene expression, hypertension, and kidney injury in diabetic mice. *Diabetes* 63(10), 3483-3496.

Aebi, H., 1984. [13] Catalase in vitro, *Methods in enzymology*. Elsevier, pp. 121-126.

Ahn, S., Chen, Y., Bredow, T., Cheung, C., Yu, F., 2017. Effects of Non-Pharmacological Treatments on Quality of Life in Parkinson's Disease: A Review. *Journal of Parkinson's disease and Alzheimer's disease* 4(1), 10.13188/12376-13922X.1000021.

Alam, J., 2006. The mammalian cap and collar family of transcription factors. *Antioxidants & redox signaling* 8(1-2), 39-42.

Alavijeh, M.S., Chishty, M., Qaiser, M.Z., Palmer, A.M., 2005. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. *NeuroRx* 2(4), 554-571.

Allbutt, H.N., Henderson, J.M., 2007. Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. *Journal of neuroscience methods* 159(2), 195-202.

Ambani, L.M., Van Woert, M.H., Murphy, S., 1975. Brain peroxidase and catalase in Parkinson disease. *Archives of neurology* 32(2), 114-118.

Ambrosi, G., Ghezzi, C., Zangaglia, R., Levandis, G., Pacchetti, C., Blandini, F., 2015. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells. *Neurobiology of disease* 82, 235-242.

Ambrosi, G., Kustrimovic, N., Siani, F., Rasini, E., Cerri, S., Ghezzi, C., Dicorato, G., Caputo, S., Marino, F., Cosentino, M., 2017. Complex changes in the innate and adaptive immunity accompany progressive degeneration of the nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine in the rat. *Neurotoxicity Research* 32(1), 71-81.

Ammar, H., Ghorab, M., El-Nahas, S., Kamel, R., 2009. Polymeric matrix system for prolonged delivery of tramadol hydrochloride, part I: physicochemical evaluation. *Aaps Pharmscitech* 10(1), 7-20.

Arlt, A., Sebens, S., Krebs, S., Geismann, C., Grossmann, M., Kruse, M., Schreiber, S., Schäfer, H., 2013. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. *Oncogene* 32(40), 4825.

- Arunachalam, A., Karthikeyan, M., Kumar, D.V., Prathap, M., Sethuraman, S., Ashutoshkumar, S., Manidipa, S., 2010. Transdermal drug delivery system: a review. *Current Pharma Research* 1(1), 70.
- Ashford, M., 2017. *Gastrointestinal tract—physiology and drug absorption*. Aulton's pharmaceuticals e-book: the design and manufacture of medicines, 300.
- Athauda, D., Maclagan, K., Skene, S.S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., 2017. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. *The Lancet* 390(10103), 1664-1675.
- Barone, M.C., Sykiotis, G.P., Bohmann, D., 2011. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a *Drosophila* model of Parkinson's disease. *Disease models & mechanisms*, dmm. 007575.
- Batool, F., Haleem, D., 2008. Serotonin1A receptor agonism in the expression of behavioral dopaminergic supersensitivity in subchronic haloperidol treated rats.
- Baviskar, D.T., Parik, V.B., Gupta, H.N., Maniyar, A.H., Jain, D.K., 2012. Design and evaluation of patches for transdermal delivery of losartan potassium. *PDA journal of pharmaceutical science and technology* 66(2), 126-135.
- Beavan, M.S., Schapira, A.H., 2013. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. *Annals of medicine* 45(8), 511-521.
- Bendikov-Bar, I., Maor, G., Filocamo, M., Horowitz, M., 2013. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. *Blood Cells, Molecules, and Diseases* 50(2), 141-145.
- Bendikov-Bar, I., Ron, I., Filocamo, M., Horowitz, M., 2011. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. *Blood Cells, Molecules, and Diseases* 46(1), 4-10.
- Berger, K., Przedborski, S., Cadet, J.L., 1991. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. *Brain Research Bulletin* 26(2), 301-307.
- Berger, Z., Perkins, S., Ambroise, C., Oborski, C., Calabrese, M., Noell, S., Riddell, D., Hirst, W.D., 2015. Tool compounds robustly increase turnover of an artificial substrate by glucocerebrosidase in human brain lysates. *PloS one* 10(3), e0119141.
- Berman, S.B., Hastings, T.G., 1999. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria. *Journal of neurochemistry* 73(3), 1127-1137.
- Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, F., 1973. Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations. *Journal of the neurological sciences* 20(4), 415-455.

- Bhardwaj, H.C., Arunachalam, M., Kumar, S.H., Navis, S., 2016. Neuroprotective and Anti-nociceptive Potential of Ambroxol in Oxaliplatin Induced Peripheral Neuropathic Pain in Rats. *Biology and Medicine* 8(2), 1-7.
- Bhaskar, H., Pranav Kapoor, R., 2010. Comparison of transdermal diclofenac patch with oral diclofenac as an analgesic modality following multiple premolar extractions in orthodontic patients: A cross over efficacy trial. *Contemporary clinical dentistry* 1(3), 158.
- Bianchi, G., Landi, M., Garattini, S., 1986. Disposition of apomorphine in rat brain areas: relationship to stereotypy. *European journal of pharmacology* 131(2), 229-236.
- Bisht, R., Joshi, B.C., Kalia, A.N., Prakash, A., 2017. Antioxidant-rich fraction of *Urtica dioica* mediated rescue of striatal mito-oxidative damage in MPTP-induced behavioral, cellular, and neurochemical alterations in rats. *Molecular neurobiology* 54(7), 5632-5645.
- Blandini, F., Levandis, G., Bazzini, E., Nappi, G., Armentero, M.T., 2007. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. *European Journal of Neuroscience* 25(2), 397-405.
- Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., Verna, J.-M., 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. *Progress in neurobiology* 65(2), 135-172.
- Bonini, N.M., Giasson, B.I., 2005. Snaring the Function of  $\alpha$ -Synuclein. *Cell* 123(3), 359-361.
- Bottenberg, P., Cleymaet, R., De Muyenck, C., Remon, J., Coomans, D., Michotte, Y., Slop, D., 1991. Development and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. *Journal of pharmacy and pharmacology* 43(7), 457-464.
- Bourque, M., Morissette, M., Di Paolo, T., 2018. Repurposing sex steroids and related drugs as potential treatment for Parkinson's disease. *Neuropharmacology*.
- Bronstein, P.M., 1972. Open-field behavior of the rat as a function of age: Cross-sectional and longitudinal investigations. *Journal of Comparative and Physiological Psychology* 80(2), 335-341.
- Bryan, H.K., Olayanju, A., Goldring, C.E., Park, B.K., 2013. The Nrf2 cell defence pathway: Keap1-dependent and-independent mechanisms of regulation. *Biochemical Pharmacology* 85(6), 705-717.
- Budi, A., Heru, S., Ahmad, Ridwan, A., Yusuf, A., 2012. Increase of Oxidative Stress and Accumulation of  $\alpha$ -Synuclein in Wistar Rat's Midbrain Treated with Rotenone. *ITB Journal* 44 A(4), 317-332.

- Burn, D., 2018. Parkinson's disease: treatment. *The Pharmaceutical Journal*, 2000. 264 (7089): p 476-479.
- Burnette, W.N., 1981. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. *Analytical biochemistry* 112(2), 195-203.
- Byrne, J.H., Heidelberger, R., Waxham, M.N., 2014. *From molecules to networks: an introduction to cellular and molecular neuroscience*. Academic Press.
- Campolo, M., Casili, G., Biundo, F., Crupi, R., Cordaro, M., Cuzzocrea, S., Esposito, E., 2017. The neuroprotective effect of dimethyl fumarate in an MPTP-mouse model of Parkinson's disease: involvement of reactive oxygen species/nuclear factor- $\kappa$ B/nuclear transcription factor related to NF-E2. *Antioxidants & redox signaling* 27(8), 453-471.
- Carrozzino, D., Morberg, B.M., Siri, C., Pezzoli, G., Bech, P., 2018. Evaluating psychiatric symptoms in Parkinson's Disease by a clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R). *Prog Neuropsychopharmacol Biol Psychiatry*. 81, 131-137.
- Carvey, P., Zhao, C., Hendey, B., Lum, H., Trachtenberg, J., Desai, B., Snyder, J., Zhu, Y., Ling, Z., 2005. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. *Eur J Neurosci*. 22(5), 1158-1168.
- Censi, R., Martena, V., Hoti, E., Malaj, L., Di Martino, P., 2012. Permeation and skin retention of quercetin from microemulsions containing Transcutol® P. *Drug development and industrial pharmacy* 38(9), 1128-1133.
- Chandra, S., Fornai, F., Kwon, H.-B., Yazdani, U., Atasoy, D., Liu, X., Hammer, R.E., Battaglia, G., German, D.C., Castillo, P.E., Südhof, T.C., 2004. Double-knockout mice for  $\alpha$ - and  $\beta$ -synucleins: Effect on synaptic functions. *Proceedings of the National Academy of Sciences of the United States of America* 101(41), 14966-14971.
- Chandrashekar, N., Rani, R.S., 2008. Physicochemical and pharmacokinetic parameters in drug selection and loading for transdermal drug delivery. *Indian journal of pharmaceutical sciences* 70(1), 94.
- Cheng, B., Yang, X., An, L., Gao, B., Liu, X., Liu, S., 2009. Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease. *Brain research* 1286, 25-31.
- Cheng, H.C., Ulane, C.M., Burke, R.E., 2010. Clinical progression in Parkinson disease and the neurobiology of axons. *Annals of neurology* 67(6), 715-725.
- Cherukuri, S., Batchu, U.R., Mandava, K., Cherukuri, V., Ganapuram, K.R., 2017. Formulation and evaluation of transdermal drug delivery of topiramate. *International journal of pharmaceutical investigation* 7(1), 10.

- Chessa, M., Caddeo, C., Valenti, D., Manconi, M., Sinico, C., Fadda, A.M., 2011. Effect of penetration enhancer containing vesicles on the percutaneous delivery of quercetin through new born pig skin. *Pharmaceutics* 3(3), 497-509.
- Chiang, C.-H., Chen, J.-L., Liu, Y.-T., Wang, D.-P., 1998. Therapeutic effect and pharmacokinetics of ketotifen transdermal delivery system. *Drug development and industrial pharmacy* 24(3), 213-217.
- Chiara, B., Laura, P., Emanuele, P., Lucilla, P., Michele, S., Carmelo, T., Aldo, O., Paolo, C., Tommaso, B., Aroldo, R., 2007. Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. *Movement Disorders* 22(10), 1481-1484.
- Choi, H.S., Lim, J.-Y., Chun, H.J., Lee, M., Kim, E.S., Keum, B., Seo, Y.S., Jeon, Y.-T., Um, S.H., Lee, H.S., 2013. The effect of polaprezinc on gastric mucosal protection in rats with ethanol-induced gastric mucosal damage: comparison study with rebamipide. *Life Sci.* 93(2), 69-77.
- Choi, S., Kim, D., Kam, T.-I., Yun, S., Kim, S., Park, H., Hwang, H., Pletnikova, O., Troncoso, J.C., Dawson, V.L., 2015. Lysosomal enzyme glucocerebrosidase protects against A $\beta$ 1-42 oligomer-induced neurotoxicity. *PloS one* 10(12), e0143854.
- Chotibut, T., Apple, D.M., Jefferis, R., Salvatore, M.F., 2012. Dopamine transporter loss in 6-OHDA Parkinson's model is unmet by parallel reduction in dopamine uptake. *PLoS One* 7(12), e52322.
- Cilurzo, F., Minghetti, P., Gennari, C.G., Casiraghi, A., Selmin, F., Montanari, L., 2014. Formulation study of a patch containing propranolol by design of experiments. *Drug development and industrial pharmacy* 40(1), 17-22.
- Cleeter, M.W., Chau, K.-Y., Gluck, C., Mehta, A., Hughes, D.A., Duchen, M., Wood, N.W., Hardy, J., Cooper, J.M., Schapira, A.H., 2013. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. *Neurochem Int.* 62(1), 1-7.
- Cooper, D.L., Harirforoosh, S., 2014. A simple high performance liquid chromatography method for determination of rebamipide in rat urine. *MethodsX* 1, 49-55.
- Cooper, D.L., Wood III, R.C., Wyatt, J.E., Harirforoosh, S., 2014. Pharmacokinetic interactions between rebamipide and selected nonsteroidal anti-inflammatory drugs in rats. *European Journal of Pharmaceutical Sciences* 53, 28-34.
- Coronel-Oliveros, C.M., Pacheco-Calderón, R., 2018. Prenatal exposure to ketamine in rats: Implications on animal models of schizophrenia. *Developmental psychobiology* 60(1), 30-42.
- Coulombe, K., Saint-Pierre, M., Cisbani, G., St-Amour, I., Gibrat, C., Giguère-Rancourt, A., Calon, F., Cicchetti, F., 2016. Partial neurorescue effects of DHA

following a 6-OHDA lesion of the mouse dopaminergic system. *The Journal of nutritional biochemistry* 30, 133-142.

Counihan, T.J., Penney, J.B., 1998. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains. *Journal of Neurology, Neurosurgery & Psychiatry* 65(2), 164-169.

Creese, B., Bell, E., Johar, I., Francis, P., Ballard, C., Aarsland, D., 2017. Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics* 177(2), 232-241.

Cuadrado, A., Moreno-Murciano, P., Pedraza-Chaverri, J., 2009. The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease. *Expert opinion on therapeutic targets* 13(3), 319-329.

Czerniczyniec, A., Bustamante, J., Lores-Arnaiz, S., 2010. Dopamine modifies oxygen consumption and mitochondrial membrane potential in striatal mitochondria. *Mol Cell Biochem.* 341(1-2), 251-257.

Dabbeni-Sala, F., Di Santo, S., Franceschini, D., Skaper, S.D., Giu, P., 2001. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. *FASEB J.* 15(1), 164-170.

Dauer, W., Przedborski, S., 2003. Parkinson's Disease: Mechanisms and Models. *Neuron* 39(6), 889-909.

Dehay, B., Martinez-Vicente, M., Caldwell, G.A., Caldwell, K.A., Yue, Z., Cookson, M.R., Klein, C., Vila, M., Bezaud, E., 2013. Lysosomal Impairment in Parkinson's Disease. *Movement disorders : official journal of the Movement Disorder Society* 28(6), 725-732.

Denenberg, V.H., 1969. Open-field behavior in the rat: what DOES it mean? *Annals of the New York Academy of Sciences* 159(1), 852-859.

Di Maio, R., Barrett, P.J., Hoffman, E.K., Barrett, C.W., Zharikov, A., Borah, A., Hu, X., McCoy, J., Chu, C.T., Burton, E.A., 2016.  $\alpha$ -Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. *Sci Transl Med.* 8(342), 342ra378.

Diao, L., Mei, Q., Xu, J.-M., Liu, X.-C., Hu, J., Jin, J., Yao, Q., Chen, M.-L., 2012. Rebamipide suppresses diclofenac-induced intestinal permeability via mitochondrial protection in mice. *World J Gastroenterol.* 18(10), 1059-1066.

Domesick, V.B., Stinus, L., Paskevich, P.A., 1983. The cytology of dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area of the rat: A light- and electron-microscopic study. *Neuroscience* 8(4), 743-765.

- Draize, J.H., Woodard, G., Calvery, H.O., 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. *Journal of pharmacology and Experimental Therapeutics* 82(3), 377-390.
- Dum, R.P., Strick, P.L., 2002. Motor areas in the frontal lobe of the primate. *Physiology & behavior* 77(4-5), 677-682.
- Duty, S., Jenner, P., 2011. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. *British journal of pharmacology* 164(4), 1357-1391.
- El-Gendy, N.A., Sabry, N.A., El-Attar, M., Omar, E., Mahmoud, M., 2008. Transdermal patch incorporating salbutamol sulphate: In vitro and clinical characterization. *Drug discoveries & therapeutics* 2(4).
- Ellman, G.L., 1959. Tissue sulfhydryl groups. *Archives of biochemistry and biophysics* 82(1), 70-77.
- Elmore, S., 2007. Apoptosis: a review of programmed cell death. *Toxicol Pathol.* 35(4), 495-516.
- Emson, P.C., Koob, G.F., 1978. The origin and distribution of dopamine-containing afferents to the rat frontal cortex. *Brain Research* 142(2), 249-267.
- Erickson, A.H., Ginns, E., Barranger, J., 1985. Biosynthesis of the lysosomal enzyme glucocerebrosidase. *Journal of biological chemistry* 260(26), 14319-14324.
- Farlow, M.R., Somogyi, M., 2011. Transdermal patches for the treatment of neurologic conditions in elderly patients: a review. *The Primary Care Companion to CNS Disorders* 13(6).
- Fernandez, A., De La Vega, A.G., Torres-Aleman, I., 1998. Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia. *Proceedings of the National Academy of Sciences* 95(3), 1253-1258.
- Fiske, C.H., Subbarow, Y., 1925. The colorimetric determination of phosphorus. *J. biol. Chem* 66(2), 375-400.
- Fortin, D.L., Nemani, V.M., Voglmaier, S.M., Anthony, M.D., Ryan, T.A., Edwards, R.H., 2005. Neural activity controls the synaptic accumulation of  $\alpha$ -synuclein. *Journal of Neuroscience* 25(47), 10913-10921.
- Fox, S.H., Katzenschlager, R., Lim, S.Y., Barton, B., de Bie, R.M., Seppi, K., Coelho, M., Sampaio, C., Committee, M.D.S.E.B.M., 2018. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. *Movement Disorders*.
- Francardo, V., Schmitz, Y., Sulzer, D., Cenci, M.A., 2017. Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease. *Experimental neurology* 298(Pt B), 137-147.

- Fukui, K., Yachi, K., Yoshida, H., Tanji, K., Matsumiya, T., Hayakari, R., Tsuruga, K., Tanaka, H., Imaizumi, T., 2017. Rebamipide reduces amyloid- $\beta$  1–42 (A $\beta$ 42) production and ameliorates A $\beta$ 43-lowered cell viability in cultured SH-SY5Y human neuroblastoma cells. *Neurosci Res.* 124, 40-50.
- Gainetdinov, R.R., Jones, S.R., Fumagalli, F., Wightman, R.M., Caron, M.G., 1998. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. *Brain Research Reviews* 26(2-3), 148-153.
- Gan, L., Johnson, J.A., 2014. Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1842(8), 1208-1218.
- Gan, L., Vargas, M.R., Johnson, D.A., Johnson, J.A., 2012. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. *Journal of Neuroscience* 32(49), 17775-17787.
- Gannu, R., Palem, C.R., Yamsani, V.V., Yamsani, S.K., Yamsani, M.R., 2010. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. *International journal of pharmaceutics* 388(1-2), 231-241.
- Garcia-Reitböck, P., Anichtchik, O., Bellucci, A., Iovino, M., Ballini, C., Fineberg, E., Ghetti, B., Della Corte, L., Spano, P., Tofaris, G.K., 2010. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. *Brain.* 133(7), 2032-2044.
- Gaur, V., Bodhankar, S.L., Mohan, V., Thakurdesai, P.A., 2013. Neurobehavioral assessment of hydroalcoholic extract of *Trigonella foenum-graecum* seeds in rodent models of Parkinson's disease. *Pharmaceutical biology* 51(5), 550-557.
- Geed, M., Garabadu, D., Ahmad, A., Krishnamurthy, S., 2014. Silibinin pretreatment attenuates biochemical and behavioral changes induced by intrastriatal MPP+ injection in rats. *Pharmacology Biochemistry and Behavior* 117, 92-103.
- Gegg, M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J., Wood, N.W., Schapira, A.H., 2012. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. *Annals of neurology* 72(3), 455-463.
- Gegg, M.E., Sweet, L., Wang, B.H., Shihabuddin, L.S., Sardi, S.P., Schapira, A.H.V., 2015. No evidence for substrate accumulation in Parkinson brains with GBA mutations. *Mov Disord* 30(8), 1085-1089.
- Gendy, A.M., Abdallah, D.M., El-Abhar, H.S., 2017. The potential curative effect of rebamipide in hepatic ischemia/reperfusion injury. *Naunyn Schmiedebergs Arch Pharmacol.* 390(7), 691-700.

- Gilmer, L.K., Roberts, K.N., Joy, K., Sullivan, P.G., Scheff, S.W., 2009. Early mitochondrial dysfunction after cortical contusion injury. *J Neurotrauma*. 26(8), 1271-1280.
- Ginns, E.I., Mak, S.K.K., Ko, N., Karlgren, J., Akbarian, S., Chou, V.P., Guo, Y., Lim, A., Samuelsson, S., LaMarca, M.L., Vazquez-DeRose, J., Manning-Boğ, A.B., 2014. Neuroinflammation and  $\alpha$ -synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. *Molecular genetics and metabolism* 111(2), 152-162.
- Girolamo, F., Coppola, C., Ribatti, D., 2017. Immunoregulatory effect of mast cells influenced by microbes in neurodegenerative diseases. *Brain, behavior, and immunity* 65, 68-89.
- Glinka, Y.Y., Youdim, M.B., 1995. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. *European Journal of Pharmacology: Environmental Toxicology and Pharmacology* 292(3-4), 329-332.
- Grabowski, G.A., 2008. Phenotype, diagnosis, and treatment of Gaucher's disease. *The Lancet* 372(9645), 1263-1271.
- Greenamyre, J.T., Sherer, T.B., Betarbet, R., Panov, A.V., 2001. Complex I and Parkinson's disease. *IUBMB life* 52(3-5), 135-141.
- Griffiths, D.E., Houghton, R.L., 1974. Studies on Energy-Linked Reactions: Modified Mitochondrial ATPase of Oligomycin-Resistant Mutants of *Saccharomyces cerevisiae*. *Eur J Biochem*. 46(1), 157-167.
- Gu, X.-S., Wang, F., Zhang, C.-Y., Mao, C.-J., Yang, J., Yang, Y.-P., Liu, S., Hu, L.-F., Liu, C.-F., 2016. Neuroprotective Effects of Paeoniflorin on 6-OHDA-Lesioned Rat Model of Parkinson's Disease. *Neurochemical Research* 41(11), 2923-2936.
- Gudas, G.K., Jaswanth, A., Bhikshapathi, D., 2016. Formulation and development of mucoadhesive tablets of rebamipide by using design of experiment. *Der Pharmacia Lettre* 8(6), 87-101.
- Guo, C., Sun, L., Chen, X., Zhang, D., 2013. Oxidative stress, mitochondrial damage and neurodegenerative diseases. *Neural Regen Res*. 8(21), 2003.
- Guo, Y., Wang, Y., Xu, L., 2015. Enhanced bioavailability of rebamipide nanocrystal tablets: Formulation and in vitro/in vivo evaluation. *asian journal of pharmaceutical sciences* 10(3), 223-229.
- Ha, J.-M., Seo, J.-W., Kim, S.-H., Kim, J.-Y., Park, C.-W., Rhee, Y.-S., Park, E.-S., 2017. Implementation of quality by design for formulation of Rebamipide gastro-retentive tablet. *AAPS PharmSciTech* 18(8), 3129-3139.
- Haavik, J., Toska, K., 1998. Tyrosine hydroxylase and Parkinson's disease. *Molecular neurobiology* 16(3), 285-309.

Hama, A.T., Plum, A.W., Sagen, J., 2010. Antinociceptive effect of ambroxol in rats with neuropathic spinal cord injury pain. *Pharmacology, biochemistry, and behavior* 97(2), 249-255.

Hambright, W.S., Fonseca, R.S., Chen, L., Na, R., Ran, Q., 2017. Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. *Redox biology* 12, 8-17.

Hamel, S.C., Pelphrey, A., 2009. Chapter 4 - PRESCHOOL YEARS, in: Carey, W.B., Crocker, A.C., Coleman, W.L., Elias, E.R., Feldman, H.M. (Eds.), *Developmental-Behavioral Pediatrics (Fourth Edition)*. W.B. Saunders, Philadelphia, pp. 39-49.

Hammond, J.C., Meador-Woodruff, J.H., Haroutunian, V., McCullumsmith, R.E., 2012. AMPA receptor subunit expression in the endoplasmic reticulum in frontal cortex of elderly patients with schizophrenia. *PLoS One* 7(6), e39190.

Hara, H., Ohta, M., Adachi, T., 2006. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. *Journal of neuroscience research* 84(4), 860-866.

Holmström, K.M., Kostov, R.V., Dinkova-Kostova, A.T., 2016. The multifaceted role of Nrf2 in mitochondrial function. *Current opinion in toxicology* 1, 80-91.

Hu, L.F., Lu, M., Tiong, C.X., Dawe, G.S., Hu, G., Bian, J.S., 2010. Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. *Aging cell* 9(2), 135-146.

Huang, B.-B., Li, G.-F., Luo, J.-H., Duan, L., Nobuaki, K., Akira, Y., 2008. Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier. *World J Gastroenterol* 14(31), 4928-4937.

Idrees, A., Rahman, N.U., Javaid, Z., Kashif, M., Aslam, I., Abbas, K., Hussain, T., 2014. In vitro evaluation of transdermal patches of flurbiprofen with ethyl cellulose. *Acta Pol Pharm* 71(2), 287-295.

Imaizumi, Y., Okada, Y., Akamatsu, W., Koike, M., Kuzumaki, N., Hayakawa, H., Nihira, T., Kobayashi, T., Ohyama, M., Sato, S., Takanashi, M., Funayama, M., Hirayama, A., Soga, T., Hishiki, T., Suematsu, M., Yagi, T., Ito, D., Kosakai, A., Hayashi, K., Shouji, M., Nakanishi, A., Suzuki, N., Mizuno, Y., Mizushima, N., Amagai, M., Uchiyama, Y., Mochizuki, H., Hattori, N., Okano, H., 2012. Mitochondrial dysfunction associated with increased oxidative stress and  $\alpha$ -synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. *Molecular Brain* 5(1), 35.

Isaac, M., Holvey, C., 2012. Transdermal patches: the emerging mode of drug delivery system in psychiatry. *Ther Adv Psychopharmacol* 2(6), 255-263.

- Ishihara, T., Tanaka, K.-I., Tashiro, S., Yoshida, K., Mizushima, T., 2010. Protective effect of rebamipide against celecoxib-induced gastric mucosal cell apoptosis. *Biochem Pharmacol.* 79(11), 1622-1633.
- Ismail, S., Mohamad, M., Syazarina, S., Nafisah, W., 2014. Hand grips strength effect on motor function in human brain using fMRI: a pilot study, *Journal of Physics: Conference Series.* IOP Publishing, p. 012005.
- Jankovic, J., Goodman, I., Safirstein, B., Schenk, D., Kinney, G., Koller, M., Ness, D., Griffith, S., Grundman, M., Soto, J., 2018. Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson's disease. *Parkinsonism & Related Disorders* 46, e25.
- Jeter, C., Rozas, N., Sadowsky, J., Jones, D., 2018. Parkinson's disease oral health module: interprofessional coordination of care. *MedEdPORTAL.* 2018; 14: 10699.
- Jing, K., Lim, K., 2012. Why is autophagy important in human diseases? *Experimental & molecular medicine* 44(2), 69.
- Joshi, G., A Johnson, J., 2012. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. *Recent patents on CNS drug discovery* 7(3), 218-229.
- Joshua, M., Adler, A., Bergman, H., 2009. The dynamics of dopamine in control of motor behavior. *Current Opinion in Neurobiology* 19(6), 615-620.
- Jun, D.-J., Kim, J., Jung, S.-Y., Song, R., Noh, J.-H., Park, Y.-S., Ryu, S.-H., Kim, J.-H., Kong, Y.-Y., Chung, J.-M., 2007. Extracellular ATP mediates necrotic cell swelling in SN4741 dopaminergic neurons through P2X7 receptors. *J Biol Chem.* 282(52), 37350-37358.
- Kakkar, A.K., Singh, H., Medhi, B., 2018. old wines in new bottles: Repurposing opportunities for Parkinson's disease. *European journal of pharmacology* 830, 115-127.
- Kakkar, P., Das, B., Viswanathan, P., 1984. A modified spectrophotometric assay of superoxide dismutase.
- Kalia, L.V., Lang, A.E., 2015. Parkinson's disease. *The Lancet* 386(9996), 896-912.
- Kayser, E.-B., Sedensky, M.M., Morgan, P.G., Hoppel, C.L., 2004. Mitochondrial oxidative phosphorylation is defective in the long-lived mutant *clk-1*. *Journal of Biological Chemistry* 279(52), 54479-54486.
- Kheradmand, A., Nayebi, A.M., Jorjani, M., Haddadi, R., 2016. Effect of WR-1065 on 6-hydroxydopamine-induced catalepsy and IL-6 level in rats. *Iran J Basic Med Sci* 19(5), 490-496.

- Kim, C., Speisky, M., Kharouba, S., 1987. Rapid and sensitive method for measuring norepinephrine, dopamine, 5-hydroxytryptamine and their major metabolites in rat brain by high-performance liquid chromatography: Differential effect of probenecid, haloperidol and yohimbine on the concentrations of biogenic amines and metabolites in various regions of rat brain. *Journal of Chromatography A* 386, 25-35.
- Kim, C.D., Hong, K.W., 1995. Preventive effect of rebamipide on gastric lesions induced by ischemia-reperfusion in the rat. *J Pharmacol Exp Ther.* 1 275(1), 340-344.
- Kim, K.T., Lee, J.-Y., Park, J.-H., Cho, H.-J., Yoon, I.-S., Kim, D.-D., 2017. Capmul MCM/Solutol HS15-based microemulsion for enhanced oral bioavailability of rebamipide. *Journal of nanoscience and nanotechnology* 17(4), 2340-2344.
- Kirik, D., Rosenblad, C., Björklund, A., 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. *Experimental neurology* 152(2), 259-277.
- Kowal, S.L., Dall, T.M., Chakrabarti, R., Storm, M.V., Jain, A., 2013. The current and projected economic burden of Parkinson's disease in the United States. *Movement Disorders* 28(3), 311-318.
- Krügel, U., Kittner, H., Franke, H., Illes, P., 2003. Purinergic modulation of neuronal activity in the mesolimbic dopaminergic system in vivo. *Synapse.* 47(2), 134-142.
- Kumar, A., Sharma, N., Gupta, A., Kalonia, H., Mishra, J., 2012. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms. *Brain research* 1471, 13-22.
- Kumar, S., Mishra, A., Krishnamurthy, S., 2017. Purinergic Antagonism Prevents Mitochondrial Dysfunction and Behavioral Deficits Associated with Dopaminergic Toxicity Induced by 6-OHDA in Rats. *Neurochemical research* 42(12), 1-17.
- Kupsch, A., Schmidt, W., Gizatullina, Z., Debska-Vielhaber, G., Voges, J., Striggow, F., Panther, P., Schwegler, H., Heinze, H.-J., Vielhaber, S., 2014. 6-Hydroxydopamine impairs mitochondrial function in the rat model of Parkinson's disease: respirometric, histological, and behavioral analyses. *J Neural Transm (Vienna).* 121(10), 1245-1257.
- Kusum Devi, V., Saisivam, S., Maria, G., Deepti, P., 2003. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. *Drug development and industrial pharmacy* 29(5), 495-503.
- Kwok, J.Y.Y., Kwan, J.C.Y., Auyeung, M., Mok, V.C.T., Chan, H.Y.L., 2017. The effects of yoga versus stretching and resistance training exercises on psychological distress for people with mild-to-moderate Parkinson's disease: study protocol for a randomized controlled trial. *Trials* 18(1), 509.

- Lamprea, M., Cardenas, F., Silveira, R., Walsh, T., Morato, S., 2003. Effects of septal cholinergic lesion on rat exploratory behavior in an open-field. *Brazilian journal of medical and biological research* 36(2), 233-238.
- Lang, A.E., Espay, A.J., 2018. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. *Movement disorders* 33(5), 660-677.
- Lastres-Becker, I., Ulusoy, A., Innamorato, N.G., Sahin, G., Rábano, A., Kirik, D., Cuadrado, A., 2012.  $\alpha$ -Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. *Human molecular genetics* 21(14), 3173-3192.
- Lefevre, G., S¸dek, G., Jhee, S., Leibowitz, M., Huang, H.L., Enz, A., Maton, S., Ereshefsky, L., Pommier, F., Schmidli, H., 2008. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. *Clinical Pharmacology & Therapeutics* 83(1), 106-114.
- Lesage, S., Brice, A., 2009. Parkinson's disease: from monogenic forms to genetic susceptibility factors. *Human molecular genetics* 18(R1), R48-R59.
- Lever, C., Burton, S., O'Keefe, J., 2006. Rearing on hind legs, environmental novelty, and the hippocampal formation. *Reviews in the Neurosciences* 17(1-2), 111-134.
- Lhommée, E., Wojtecki, L., Czernecki, V., Witt, K., Maier, F., Tonder, L., Timmermann, L., Hlbig, T.D., Pineau, F., Durif, F., 2018. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. *The Lancet Neurology* 17(3), 223-231.
- Li, L.-y., Zhao, X.-l., Fei, X.-f., Gu, Z.-l., Qin, Z.-h., Liang, Z.-q., 2008. Bilobalide inhibits 6-OHDA-induced activation of NF- $\kappa$ B and loss of dopaminergic neurons in rat substantia nigra. *Acta Pharmacologica Sinica* 29(5), 539-547.
- Li, X., Dong, C., Hoffmann, M., Garen, C.R., Cortez, L.M., Petersen, N.O., Woodside, M.T., 2019. Early stages of aggregation of engineered  $\alpha$ -synuclein monomers and oligomers in solution. *Scientific reports* 9(1), 1734.
- Lindholm, P., Voutilainen, M.H., Laurén, J., Peränen, J., Leppänen, V.-M., Andressoo, J.-O., Lindahl, M., Janhunen, S., Kalkkinen, N., Timmusk, T., 2007. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. *Nature* 448(7149), 73.
- Liu, Y., Peterson, D.A., Kimura, H., Schubert, D., 1997. Mechanism of cellular 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction. *Journal of neurochemistry* 69(2), 581-593.
- Liu, Z., Cai, W., Lang, M., Yan, R., Li, Z., Zhang, G., Yu, P., Wang, Y., Sun, Y., Zhang, Z., 2017. Neuroprotective Effects and Mechanisms of Action of

Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model. *Journal of Molecular Neuroscience* 61(4), 498-510.

Löschmann, P.-A., Chong, P.N., Nomoto, M., Tepper, P.G., Horn, A.S., Jenner, P., Marsden, C.D., 1989. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. *European journal of pharmacology* 166(3), 373-380.

Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the Folin phenol reagent. *Journal of biological chemistry* 193(1), 265-275.

Maday, S., Twelvetrees, A.E., Moughamian, A.J., Holzbaur, E.L.F., 2014. Axonal Transport: Cargo-Specific Mechanisms Of Motility And Regulation. *Neuron* 84(2), 292-309.

Maegawa, G.H., Tropak, M.B., Buttner, J.D., Rigat, B.A., Fuller, M., Pandit, D., Tang, L., Kornhaber, G.J., Hamuro, Y., Clarke, J.T., 2009. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. *Journal of Biological Chemistry* 284(35), 23502-23516.

Malaiya, M.K., Jain, A., Pooja, H., Jain, A., Jain, D., 2018. Controlled delivery of rivastigmine using transdermal patch for effective management of alzheimer's disease. *Journal of Drug Delivery Science and Technology* 45, 408-414.

Malerba, M., Ragnoli, B., 2008. Ambroxol in the 21st century: pharmacological and clinical update. *Expert opinion on drug metabolism & toxicology* 4(8), 1119-1129.

Manecka, D.-L., Vanderperre, B., Fon, E.A., Durcan, T.M., 2017. The Neuroprotective Role of Protein Quality Control in Halting the Development of Alpha-Synuclein Pathology. *Frontiers in molecular neuroscience* 10, 311.

Manglani, U., Khan, I., Soni, K., Loya, P., Saraf, M., 2006. Development and validation of HPLC-UV method for the estimation of rebamipide in human plasma. *Indian journal of pharmaceutical sciences* 68(4).

Maor, G., Cabasso, O., Krivoruk, O., Rodriguez, J., Steller, H., Segal, D., Horowitz, M., 2016. The contribution of mutant GBA to the development of Parkinson disease in *Drosophila*. *Human Molecular Genetics* 25(13), 2712-2727.

Marin, C., Aguilar, E., 2011. In vivo 6-OHDA-induced neurodegeneration and nigral autophagic markers expression. *Neurochemistry international* 58(4), 521-526.

Mazzulli, J.R., Xu, Y.-H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A., Krainc, D., 2011. Gaucher disease glucocerebrosidase and  $\alpha$ -synuclein form a bidirectional pathogenic loop in synucleinopathies. *Cell*. 146(1), 37-52.

- McMahon, B., Aflaki, E., Sidransky, E., 2016. Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism. *Neural Regeneration Research* 11(11), 1760-1761.
- McNeill, A., Magalhaes, J., Shen, C., Chau, K.-Y., Hughes, D., Mehta, A., Foltynie, T., Cooper, J.M., Abramov, A.Y., Gegg, M., 2014. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. *Brain* 137(5), 1481-1495.
- Meyer, O.A., Tilson, H., Byrd, W., Riley, M., 1979. A method for the routine assessment of fore-and hindlimb grip strength of rats and mice. *Neurobehavioral toxicology* 1(3), 233-236.
- Migdalska-Richards, A., Daly, L., Bezard, E., Schapira, A.H., 2016. Ambroxol effects in glucocerebrosidase and  $\alpha$ -synuclein transgenic mice. *Annals of neurology* 80(5), 766-775.
- Migdalska-Richards, A., Schapira, A.H., 2016. The relationship between glucocerebrosidase mutations and Parkinson disease. *Journal of neurochemistry* 139(S1), 77-90.
- Mirfakhrai, F., Mohammadi, Z.F., Mohammadi, H.F., 2017. Forced Exercise in Combination with 1, 25-dihydroxyvitamin D3 Before Induction of 6-hydroxydopamine Protects Dopaminergic Neurons in Rats Model of Parkinson's Disease. *Zahedan Journal of Research in Medical Sciences* 19(4).
- Mishra, A., Chandravanshi, L.P., Trigun, S.K., Krishnamurthy, S., 2018. Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson's disease symptoms. *Biochemical Pharmacology* 155, 479-493.
- Mishra, A., Krishnamurthy, S., 2019. Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with  $\alpha$ -Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats. *Neurotoxicity Research*.
- Mizuno, Y., Yoshino, H., Ikebe, S.I., Hattori, N., Kobayashi, T., Shimoda-Matsubayashi, S., Matsumine, H., Kondo, T., 1998. Mitochondrial dysfunction in Parkinson's disease. *Annals of neurology* 44(S1 1), S99-S109.
- Moon, S.-J., Min, J.-K., Cho, M.-L., 2013. THU0103 Rebamipide Attenuates Arthritis Severity in Experimental Arthritis Model Via Reciprocal Regulation of Th17-Regulatory T Cells and Mediating Heme Oxygenase-1 Via NRF2 Activation. *Annals of the Rheumatic Diseases* 72(Suppl 3), A197-A197.
- Moon, S.-J., Woo, Y.-J., Jeong, J.-H., Park, M.-K., Oh, H.-J., Park, J.-S., Kim, E.-K., Cho, M.-L., Park, S.-H., Kim, H.-Y., 2012. Rebamipide attenuates pain severity and cartilage degeneration in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes. *Osteoarthritis and cartilage* 20(11), 1426-1438.

- Moon, S.J., Park, J.S., Woo, Y.J., Lim, M.A., Kim, S.M., Lee, S.Y., Kim, E.K., Lee, H.J., Lee, W.S., Park, S.H., 2014. Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of Th17/Treg cell differentiation and heme oxygenase 1 induction. *Arthritis & rheumatology* 66(4), 874-885.
- Moore, D.J., West, A.B., Dawson, V.L., Dawson, T.M., 2005. Molecular pathophysiology of Parkinson's disease. *Annu. Rev. Neurosci.* 28, 57-87.
- Morfini, G.A., Burns, M.R., Stenoien, D.L., Brady, S.T., 2012. Chapter 8 - Axonal Transport, *Basic Neurochemistry (Eighth Edition)*. Academic Press, New York, pp. 146-164.
- Muddana, N.R., Benade, V., Paliwal, P., Muppidi, A.B., Subramanian, R., Chillakur, M., Kandikere, V., Bhyrapuneni, G., Nirogi, R., 2014. Neuro-pharmacokinetics based prediction of p-glycoprotein liability in early drug discovery, *Drug Metabolism Reviews*. Informa Healthcare Telephone House, 69-77 Paul Street, London EC2A 4LQ, England, pp. 111-112.
- Müller, T., 2012. Drug therapy in patients with Parkinson's disease. *Transl Neurodegener.* 1(1), 10.
- Murray, M.D., Callahan, C.M., 2003. Improving medication use for older adults: an integrated research agenda. *Annals of Internal Medicine* 139(5\_Part\_2), 425-429.
- Nagano, Y., Matsui, H., Muramatsu, M., Shimokawa, O., Shibahara, T., Yanaka, A., Nakahara, A., Matsuzaki, Y., Tanaka, N., Nakamura, Y., 2005. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. *Dig Dis Sci.* 50(1), S76-S83.
- Naik, A., Kalia, Y.N., Guy, R.H., 2000. Transdermal drug delivery: overcoming the skin's barrier function. *Pharmaceutical science & technology today* 3(9), 318-326.
- Nair, R.S., Ling, T.N., Shukkoor, M.S.A., Manickam, B., 2013. Matrix type transdermal patches of captopril: Ex vivo permeation studies through excised rat skin. *Journal of Pharmacy Research* 6(7), 774-779.
- Naito, Y., Yoshikawa, T., 2010. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. *Expert review of gastroenterology & hepatology* 4(3), 261-270.
- Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., Sakumi, K., 2007. Oxidative damage in nucleic acids and Parkinson's disease. *J Neurosci Res.* 85(5), 919-934.
- Nakaso, K., Nakamura, C., Sato, H., Imamura, K., Takeshima, T., Nakashima, K., 2006. Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. *Biochemical and biophysical research communications* 339(3), 915-922.
- Ngo, L., Yoo, H.-D., Tran, P., Cho, H.-Y., Lee, Y.-B., 2017. Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the

characterization of atypical complex absorption kinetics. *Journal of pharmacokinetics and pharmacodynamics* 44(4), 291-303.

Nicholls, D.G., Ward, M.W., 2000. Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. *Trends Neurosci.* 23(4), 166-174.

Nutt, J.G., Carter, J.H., Sexton, G.J., 2004. The dopamine transporter: importance in Parkinson's disease. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society* 55(6), 766-773.

Obae, K., Yoshida, N., Kajihara, K., 2017. Transdermal absorption enhancer and transdermal absorption enhancement aid. Google Patents.

Ohashi, Y., Aihara, E., Takasuka, H., Takahashi, K., Takeuchi, K., 2009. Antral ulcers induced by alendronate, a nitrogen-containing bisphosphonate, in rat stomachs—prophylactic effect of rebamipide. *J Physiol Pharmacol.* 60(3), 85-93.

Olanow, C.W., Stern, M.B., Sethi, K., 2009. The scientific and clinical basis for the treatment of Parkinson disease (2009). *Neurology* 72(21 Supplement 4), S1.

Old, S.L., Johnson, M.A., 1989. Methods of microphotometric assay of succinate dehydrogenase and cytochrome c oxidase activities for use on human skeletal muscle. *Histochem J.* 21(9-10), 545-555.

Osellame, L.D., Rahim, A.A., Hargreaves, I.P., Gegg, M.E., Richard-Londt, A., Brandner, S., Waddington, S.N., Schapira, A.H., Duchen, M.R., 2013. Mitochondria and quality control defects in a mouse model of Gaucher disease—links to Parkinson's disease. *Cell metabolism* 17(6), 941-953.

Parhi, R., Padilam, S., 2018. In vitro permeation and stability studies on developed drug-in-adhesive transdermal patch of simvastatin. *Bulletin of Faculty of Pharmacy, Cairo University* 56(1), 26-33.

Parhi, R., Suresh, P., 2016. Transdermal delivery of Diltiazem HCl from matrix film: Effect of penetration enhancers and study of antihypertensive activity in rabbit model. *Journal of advanced research* 7(3), 539-550.

Parikh, D.K., Ghosh, T.K., 2005. Feasibility of transdermal delivery of fluoxetine. *AAPS PharmSciTech* 6(2), E144-E149.

Park, A., Stacy, M., 2009. Non-motor symptoms in Parkinson's disease. *Journal of neurology* 256(3), 293-298.

Parker, N.F., Cameron, C.M., Taliaferro, J.P., Lee, J., Choi, J.Y., Davidson, T.J., Daw, N.D., Witten, I.B., 2016. Reward and choice encoding in terminals of midbrain dopamine neurons depends on striatal target. *Nat Neurosci.* 19(6), 845-854.

Patki, G., Lau, Y.-S., 2011. Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. *Pharmacol Biochem Behav.* 99(4), 704-711.

- Paxinos, G., Watson, C., 1998. The rat brain in stereotaxic coordinates. Academic Press, San Diego.
- Pereira, D.M., Valentão, P., Andrade, P.B., 2018. Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones. *Chemical science* 9(7), 1740-1752.
- Perez-Pardo, P., de Jong, E.M., Broersen, L.M., van Wijk, N., Attali, A., Garssen, J., Kraneveld, A.D., 2017. Promising effects of neurorestorative diets on motor, cognitive, and gastrointestinal dysfunction after symptom development in a mouse model of Parkinson's disease. *Frontiers in aging neuroscience* 9, 57.
- Phadtare, D.G., Phadtare, G.N., Nilesh, B.S., & Asawat, M., 2014. Hypromellose - A Choice Of Polymer In Extended Release Tablet Formulation. *World Journal Of Pharmacy And Pharmaceutical Sciences* 3(9), 551-566.
- Pires, A.O., Teixeira, F.G., Mendes-Pinheiro, B., Serra, S.C., Sousa, N., Salgado, A.J., 2017. Old and new challenges in Parkinson's disease therapeutics. *Progress in neurobiology* 156, 69-89.
- Prabhakara, P., Koland, M., Vijaynarayana, K., Harish, N., Shankar, G., Ahmed, M.G., Satyanarayana, D., 2010. Preparation and evaluation of Transdermal patches of Papaverine hydrochloride. *International Journal of Research in Pharmaceutical Sciences* 1(3), 259-266.
- Pradhan, R., Tran, T.H., Choi, J.Y., Choi, I.S., Choi, H.-G., Yong, C.S., Kim, J.O., 2015. Development of a rebamipide solid dispersion system with improved dissolution and oral bioavailability. *Archives of Pharmacal research* 38(4), 522-533.
- Pradhan, S.D., Brewer, B.R., Carvell, G.E., Sparto, P.J., Delitto, A., Matsuoka, Y., 2010. Assessment of fine motor control in individuals with Parkinson's disease using force tracking with a secondary cognitive task. *J Neurol Phys Ther.* 34(1), 32-40.
- Prajapati, S.K., Garabadu, D., Krishnamurthy, S., 2017. Coenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats. *Neurotoxicity Research* 31(4), 478-492.
- Prajapati, S.T., Patel, C.G., Patel, C.N., 2011. Formulation and evaluation of transdermal patch of repaglinide. *ISRN Pharm* 2011, 651909-651909.
- Prausnitz, M.R., Langer, R., 2008. Transdermal drug delivery. *Nature biotechnology* 26(11), 1261.
- Pringsheim, T., Jette, N., Frolkis, A., Steeves, T.D., 2014. The prevalence of Parkinson's disease: A systematic review and meta-analysis. *Movement disorders* 29(13), 1583-1590.
- Przedbroski, S., Leviver, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D., Togasaki, D., 1995. Dose-dependent lesions of the dopaminergic nigrostriatal

pathway induced by intrastriatal injection of 6-hydroxydopamine. *Neuroscience* 67(3), 631-647.

Qian, Y., Lei, G., Castellanos, F.X., Forssberg, H., Heijtz, R.D., 2010. Deficits in fine motor skills in a genetic animal model of ADHD. *Behav Brain Funct.* 6, 51-51.

Raghuraman, S., Velrajan, G., Ravi, R., Jeyabalan, B., Johnson, D.B., Sankar, V., 2002. Design and evaluation of propranolol hydrochloride buccal films. *Indian journal of pharmaceutical sciences* 64(1), 32.

Ramadan, E., Borg, T., Abdelghani, G., Saleh, N., 2018. Design and in vivo pharmacokinetic study of a newly developed lamivudine transdermal patch. *Future Journal of Pharmaceutical Sciences* 4(2), 166-174.

Ramsey, C.P., Glass, C.A., Montgomery, M.B., Lindl, K.A., Ritson, G.P., Chia, L.A., Hamilton, R.L., Chu, C.T., Jordan-Sciutto, K.L., 2007. Expression of Nrf2 in neurodegenerative diseases. *Journal of Neuropathology & Experimental Neurology* 66(1), 75-85.

Raza, H., John, A., 2012. Implications of altered glutathione metabolism in aspirin-induced oxidative stress and mitochondrial dysfunction in HepG2 cells. *PLoS One* 7(4), e36325-e36325.

Reczek, D., Schwake, M., Schröder, J., Hughes, H., Blanz, J., Jin, X., Brondyk, W., Van Patten, S., Edmunds, T., Saftig, P., 2007. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of  $\beta$ -glucocerebrosidase. *Cell.* 131(4), 770-783.

Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S.B., Del-Bel, E., Raisman-Vozari, R., 2017. Novel tactics for neuroprotection in Parkinson's disease: role of antibiotics, polyphenols and neuropeptides. *Progress in neurobiology* 155, 120-148.

Reidling, J.C., Relaño-Ginés, A., Holley, S.M., Ochaba, J., Moore, C., Fury, B., Lau, A., Tran, A.H., Yeung, S., Salamati, D., 2018. Human neural stem cell transplantation rescues functional deficits in R6/2 and Q140 Huntington's disease mice. *Stem cell reports* 10(1), 58-72.

Richter, F., Fleming, S.M., Watson, M., Lemesre, V., Pellegrino, L., Raney, B., Zhu, C., Mortazavi, F., Mulligan, C.K., Sioshansi, P.C., 2014. A GCcase chaperone improves motor function in a mouse model of synucleinopathy. *Neurotherapeutics* 11(4), 840-856.

Robinson, T.E., Whishaw, I.Q., 1988. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. *Brain Research* 450(1-2), 209-224.

Rocha, E.M., Smith, G.A., Park, E., Cao, H., Brown, E., Hallett, P., Isacson, O., 2015a. Progressive decline of glucocerebrosidase in aging and Parkinson's disease. *Annals of clinical and translational neurology* 2(4), 433-438.

- Rocha, E.M., Smith, G.A., Park, E., Cao, H., Brown, E., Hayes, M.A., Beagan, J., McLean, J.R., Izen, S.C., Perez-Torres, E., 2015b. Glucocerebrosidase gene therapy prevents  $\alpha$ -synucleinopathy of midbrain dopamine neurons. *Neurobiology of disease* 82, 495-503.
- Rocha, E.M., Smith, G.A., Park, E., Cao, H., Graham, A.-R., Brown, E., McLean, J.R., Hayes, M.A., Beagan, J., Izen, S.C., 2015c. Sustained systemic glucocerebrosidase inhibition induces brain  $\alpha$ -synuclein aggregation, microglia and complement C1q activation in mice. *Antioxidants & redox signaling* 23(6), 550-564.
- Rodriguez-Oroz, M.C., Jahanshahi, M., Krack, P., Litvan, I., Macias, R., Bezard, E., Obeso, J.A., 2009. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. *The Lancet Neurology* 8(12), 1128-1139.
- Rozas, G., Guerra, M., Labandeira-Garcia, J., 1997. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. *Brain Research Protocols* 2(1), 75-84.
- Ryu, J., Zhang, R., Hong, B.-H., Yang, E.-J., Kang, K.A., Choi, M., Kim, K.C., Noh, S.-J., Kim, H.S., Lee, N.-H., 2013. Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity. *PLoS One* 8(8), e71178.
- Sakurai, K., Osaka, T., Yamasaki, K., 1998. Protection by rebamipide against acetic acid-induced colitis in rats: relationship with its antioxidative activity. *Dig Dis Sci.* 43(9 Suppl), 125S-133S.
- Samaiya, P.K., Krishnamurthy, S., 2015. Characterization of mitochondrial bioenergetics in neonatal anoxic model of rats. *Journal of bioenergetics and biomembranes* 47(3), 217-222.
- Samaiya, P.K., Narayan, G., Kumar, A., Krishnamurthy, S., 2016. Neonatal anoxia leads to time dependent progression of mitochondrial linked apoptosis in rat cortex and associated long term sensorimotor deficits. *Int J Dev Neurosci.* 52, 55-65.
- Samaiya, P.K., Narayan, G., Kumar, A., Krishnamurthy, S., 2018. 2, 4 Dinitrophenol Attenuates Mitochondrial Dysfunction and Improves Neurobehavioral Outcomes Postanoxia in Neonatal Rats. *Neurotox Res.* 34(1), 121-136.
- Sambrook, J., Russell, D.W., 2001. *Molecular cloning: a laboratory manual*. Cold spring harbor laboratory press, New York.
- Sanberg, P.R., Bunsey, M.D., Giordano, M., Norman, A.B., 1988. The catalepsy test: its ups and downs. *Behavioral neuroscience* 102(5), 748-759.
- Sanchez-Martinez, A., Beavan, M., Gegg, M.E., Chau, K.-Y., Whitworth, A.J., Schapira, A.H.V., 2016. Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. *Scientific Reports* 6, 31380.

Sanders, A., Hemmelgarn, H., Melrose, H.L., Hein, L., Fuller, M., Clarke, L.A., 2013. Transgenic mice expressing human glucocerebrosidase variants: Utility for the study of Gaucher disease. *Blood Cells, Molecules, and Diseases* 51(2), 109-115.

Santos, D.M., Tiscornia, G., 2017. Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned? *International Journal of Molecular Sciences* 18(4), 888.

Saravanan, K.S., Sindhu, K.M., Senthilkumar, K.S., Mohanakumar, K.P., 2006. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. *Neurochemistry international* 49(1), 28-40.

Sardi, S.P., Cedarbaum, J.M., Brundin, P., 2018. Targeted therapies for Parkinson's disease: from genetics to the clinic. *Movement Disorders* 33(5), 684-696.

Sardi, S.P., Clarke, J., Viel, C., Chan, M., Tamsett, T.J., Treleaven, C.M., Bu, J., Sweet, L., Passini, M.A., Dodge, J.C., 2013. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. *Proceedings of the National Academy of Sciences* 110(9), 3537-3542.

Sarkar, G., Saha, N.R., Roy, I., Bhattacharyya, A., Bose, M., Mishra, R., Rana, D., Bhattacharjee, D., Chattopadhyay, D., 2014. Taro corms mucilage/HPMC based transdermal patch: an efficient device for delivery of diltiazem hydrochloride. *International journal of biological macromolecules* 66, 158-165.

Sauer, H., Oertel, W., 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. *Neuroscience* 59(2), 401-415.

Savjani, K.T., Gajjar, A.K., Savjani, J.K., 2012. Drug solubility: importance and enhancement techniques. *ISRN pharmaceuticals* 2012.

Schapira, A., Cooper, J., Dexter, D., Clark, J., Jenner, P., Marsden, C., 1990. Mitochondrial complex I deficiency in Parkinson's disease. *Journal of neurochemistry* 54(3), 823-827.

Schapira, A.H.V., 2015. Glucocerebrosidase and Parkinson disease: Recent advances. *Molecular and cellular neurosciences* 66(0 0), 37-42.

Schwab, R.S., England, A.C., Peterson, E., 1959. Akinesia in Parkinson's disease. *Neurology* 9(1), 65.

Sebaugh, J., 2011. Guidelines for accurate EC50/IC50 estimation. *Pharmaceutical statistics* 10(2), 128-134.

Sedaghat, R., Roghani, M., Khalili, M., 2014. Neuroprotective effect of thymoquinone, the nigella sativa bioactive compound, in 6-hydroxydopamine-

induced hemi-parkinsonian rat model. Iranian journal of pharmaceutical research: IJPR 13(1), 227-234.

Sedlak, J., Lindsay, R.H., 1968. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Analytical biochemistry 25, 192-205.

Seibenhener, M.L., Wooten, M.C., 2015. Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice. Journal of visualized experiments : JoVE(96), e52434-e52434.

Sethi, B., Mazumder, R., In-Vivo Characterization Of Transdermal Patches Of Aliskiren Hemifumarate For Treatment Of Hypertension. International Journal Of Pharmaceutical Sciences And Research 10(4), 1929-1934.

Shabbir, M., Ali, S., Nabeel Shahid, M., Rehman, K., Amin, M., Raza, M., 2014. Formulation Considerations And Factors Affecting Transdermal Drug Delivery System-A Review.

Shapiro, B.L., Feigal, R.J., Lam, L., 1979. Mitochondrial NADH dehydrogenase in cystic fibrosis. Proc Natl Acad Sci U S A. 76(6), 2979-2983.

Sheth, N.S., Mistry, R.B., 2011. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of eugenol. Journal of Applied Pharmaceutical Science 1(3), 96.

Shi, Y., Zou, M., An, Y., Ji, Z., Gao, P., Cheng, G., 2013. A potent preparation method combining neutralization with microfluidization for rebamipide nanosuspensions and its in vivo evaluation. Drug development and industrial pharmacy 39(7), 996-1004.

Shimada, S., Kitayama, S., Walther, D., Uhl, G., 1992. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Molecular Brain Research 13(4), 359-362.

Shin, B.S., Kim, C.H., Jun, Y.S., Yoon, C.H., Rho, J.I., Lee, K.C., Han, H.S., Yoo, S.D., 2004. Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats. Drug Dev Ind Pharm. 30(8), 869-876.

Shioya, Y., Kashiya, E., Okada, K., Kusumoto, N., Abe, Y., Uchida, M., Shimizu, T., 1989. Metabolic fate of the anti-ulcer agent, (±)-2-(4-chlorobenzoylamino)-3-[2 (1H)-quinolinon-4-yl] propionic acid (OPC-12759): Absorption, distribution, and excretion in rats and dogs. Iyakuin Kenkyu 20, 522-533.

Shioya, Y., Shimizu, T., 1988. High-performance liquid chromatographic procedure for the determination of a new anti-gastric ulcer agent, 2-(4-chlorobenzoylamino)-3-[2 (1H)-quinolinon-4-yl] propionic acid, in human plasma and urine. J Chromatogr B Biomed Sci Appl 434(1), 283-287.

- Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., 2009. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *New England Journal of Medicine* 361(17), 1651-1661.
- Sieb, J.P., Themann, P., Warnecke, T., Lauterbach, T., Berkels, R., Grieger, F., Lorenzl, S., 2015. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study. *Current medical research and opinion* 31(5), 967-974.
- Silveira, C., MacKinley, J., Coleman, K., Li, Z., Finger, E., Bartha, R., Morrow, S., Wells, J., Borrie, M., Tirona, R., 2019. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. *BMC neurology* 19(1), 20.
- Simuni, T., Fiske, B., Merchant, K., Coffey, C., Matthews, H., Wyse, R., Brundin, P., Rafaloff, G., Simon, D., Schwarzschild, M., 2018. A Phase 2a study of nilotinib in patients with advanced and early Parkinson's disease. Study design (P5. 068). *Mov Disord* 33.
- Singh, A., Bali, A., 2016. Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride. *Journal of Analytical Science and Technology* 7(1), 25.
- Singh, I.N., Sullivan, P.G., Deng, Y., Mbye, L.H., Hall, E.D., 2006. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. *J Cereb Blood Flow Metab* 26(11), 1407-1418.
- Sirota, R., Gibson, D., Kohen, R., 2015. The role of the catecholic and the electrophilic moieties of caffeic acid in Nrf2/Keap1 pathway activation in ovarian carcinoma cell lines. *Redox biology* 4, 48-59.
- Smith, Y., Wichmann, T., Factor, S.A., DeLong, M.R., 2012. Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. *Neuropsychopharmacology*. 37(1), 213-246.
- Smolinsky, A., L. Bergner, C., L. LaPorte, J., Kalueff, A., 2009. Analysis of Grooming Behavior and Its Utility in Studying Animal Stress, Anxiety, and Depression.
- Sofic, E., Lange, K.W., Jellinger, K., Riederer, P., 1992. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. *Neuroscience letters* 142(2), 128-130.
- Som, I., Bhatia, K., Yasir, M., 2012. Status of surfactants as penetration enhancers in transdermal drug delivery. *J Pharm Bioallied Sci* 4(1), 2-9.
- Son, G., Han, J., 2018. Roles of mitochondria in neuronal development. *BMB reports* 51(11), 549.

- Song, J.H., Han, Y.-M., Kim, W.H., Park, J.-M., Jeong, M., Go, E.J., Hong, S.P., Hahm, K.B., 2016. Oxidative stress from reflux esophagitis to esophageal cancer: the alleviation with antioxidants. *Free radical research* 50(10), 1071-1079.
- Sossi, V., de la Fuente-Fernández, R., Schulzer, M., Troiano, A.R., Ruth, T.J., Stoessl, A.J., 2007. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society* 62(5), 468-474.
- Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., Goedert, M., 1998.  $\alpha$ -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. *Proceedings of the National Academy of Sciences* 95(11), 6469-6473.
- Stern, Y., Mayeux, R., Rosen, J., Ilson, J., 1983. Perceptual motor dysfunction in Parkinson's disease: a deficit in sequential and predictive voluntary movement. *Journal of Neurology, Neurosurgery & Psychiatry* 46(2), 145-151.
- Stojančević, M., Pavlović, N., Goločorbin-Kon, S., Mikov, M., 2013. Application of bile acids in drug formulation and delivery. *Frontiers in Life Science* 7(3-4), 112-122.
- Stojkowska, I., Krainc, D., Mazzulli, J.R., 2018. Molecular mechanisms of  $\alpha$ -synuclein and GBA1 in Parkinson's disease. *Cell and Tissue Research* 373(1), 51-60.
- Suksaeree, J., Siripornpinyo, P., Chaiprasit, S., 2017. Formulation, Characterization, and In Vitro Evaluation of Transdermal Patches for Inhibiting Crystallization of Mefenamic Acid. *Journal of Drug Delivery* 2017, 7.
- Sunderman, F., Marzouk, A., Hopfer, S., Zaharia, O., Reid, M., 1985. Increased lipid peroxidation in tissues of nickel chloride-treated rats. *Ann Clin Lab Sci.* 15(3), 229-236.
- Sykiotis, G.P., Bohmann, D., 2010. Stress-activated cap'n'collar transcription factors in aging and human disease. *Sci. Signal.* 3(112), re3-re3.
- Takeshita, H., Yamamoto, K., Nozato, S., Inagaki, T., Tsuchimochi, H., Shirai, M., Yamamoto, R., Imaizumi, Y., Hongyo, K., Yokoyama, S., 2017. Modified forelimb grip strength test detects aging-associated physiological decline in skeletal muscle function in male mice. *Scientific Reports* 7, 42323.
- Tufekci, K.U., Civi Bayin, E., Genc, S., Genc, K., 2011. The Nrf2/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson's disease. *Parkinson's disease* 2011.
- Ubaidulla, U., Reddy, M.V., Ruckmani, K., Ahmad, F.J., Khar, R.K., 2007. Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. *AAPS PharmSciTech* 8(1), E13-E20.

- Uchiyama, M., Mihara, M., 1978. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. *Anal Biochem.* 86(1), 271-278.
- Ungerstedt, U., 1971. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. *Acta Physiologica* 82(S367), 69-93.
- Van Den Buuse, M., Veldhuis, H.D., De Boer, S., Versteeg, D.H., De Jong, W., 1986. Central 6-OHDA affects both open-field exploratory behaviour and the development of hypertension in SHR. *Pharmacology Biochemistry and Behavior* 24(1), 15-21.
- Velayudhan, L., Ffytche, D., Ballard, C., Aarsland, D., 2017. New Therapeutic Strategies for Lewy Body Dementias. *Current Neurology and Neuroscience Reports* 17(9), 68.
- Vervoort, G., Bengevoord, A., Strouwen, C., Bekkers, E.M., Heremans, E., Vandenberghe, W., Nieuwboer, A., 2016. Progression of postural control and gait deficits in Parkinson's disease and freezing of gait: a longitudinal study. *Parkinsonism & related disorders* 28, 73-79.
- Vijayakumar, D., Jankovic, J., 2016. Drug-induced dyskinesia, part 1: treatment of levodopa-induced dyskinesia. *Drugs* 76(7), 759-777.
- Voutilainen, M.H., De Lorenzo, F., Stepanova, P., Bäck, S., Yu, L.-Y., Lindholm, P., Pörsti, E., Saarma, M., Männistö, P.T., Tuominen, R.K., 2017. Evidence for an additive neurorestorative effect of simultaneously administered CDNF and GDNF in hemiparkinsonian rats: implications for different mechanism of action. *eNeuro* 4(1), ENEURO.0117-0116.2017.
- Walther, S., Strik, W., 2012. Motor Symptoms and Schizophrenia. *Neuropsychobiology* 66(2), 77-92.
- Waters, C., 2013. The development of the rotigotine transdermal patch: a historical perspective. *Neurologic clinics* 31(3), S37-S50.
- Whishaw, I.Q., Tomie, J.-A., Ladowsky, R.L., 1990. Red nucleus lesions do not affect limb preference or use, but exacerbate the effects of motor cortex lesions on grasping in the rat. *Behavioural Brain Research* 40(2), 131-144.
- Williams, A.C., Barry, B.W., 2012. Penetration enhancers. *Advanced drug delivery reviews* 64, 128-137.
- Williamson, C.D., Wong, D.S., Bozidis, P., Zhang, A., Colberg-Poley, A.M., 2015. Isolation of Endoplasmic Reticulum, Mitochondria, and Mitochondria-Associated Membrane and Detergent Resistant Membrane Fractions from Transfected Cells and from Human Cytomegalovirus-Infected Primary Fibroblasts. *Current protocols in cell biology* 68(1), 3.27. 21-23.27. 33.
- Wrasidlo, W., Tsigelny, I.F., Price, D.L., Dutta, G., Rockenstein, E., Schwarz, T.C., Ledolter, K., Bonhaus, D., Paulino, A., Eleuteri, S., 2016. A de novo compound

targeting  $\alpha$ -synuclein improves deficits in models of Parkinson's disease. *Brain* 139(12), 3217-3236.

Yap, T.L., Gruschus, J.M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., Lee, J.C., 2011.  $\alpha$ -Synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. *J Biol Chem*. 286(32), 28080-28088.

Yuan, H., Sarre, S., Ebinger, G., Michotte, Y., 2004. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease. *Brain Research* 1026(1), 95-107.

Zaitone, S.A., Abo-Elmatty, D.M., Shaalan, A.A., 2012. Acetyl-L-carnitine and  $\alpha$ -lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. *Pharmacology Biochemistry and Behavior* 100(3), 347-360.

Zamzami, N., Hirsch, T., Dallaporta, B., Petit, P.X., Kroemer, G., 1997. Mitochondrial Implication in Accidental and Programmed Cell Death: Apoptosis and Necrosis. *J Bioenerg Biomembr*. 29(2), 185-193.

Zhao, J.-H., Fu, J.-H., Wang, S.-M., Su, C.-H., Shan, Y., Kong, S.-J., Wang, Y., Lu, W.-L., Zhang, H., Zhang, S., 2007. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. *International journal of pharmaceutics* 337(1-2), 88-101.

Zhao, Q., Cai, D., Bai, Y., 2013. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease. *International journal of molecular medicine* 32(4), 883-891.

Zhao, X., Zhai, S., An, M.-S., Wang, Y.-H., Yang, Y.-F., Ge, H.-Q., Liu, J.-H., Pu, X.-P., 2013. Neuroprotective effects of protocatechuic aldehyde against neurotoxin-induced cellular and animal models of Parkinson's disease. *PloS one* 8(10), e78220.

Zhu, H., Itoh, K., Yamamoto, M., Zweier, J.L., Li, Y., 2005. Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: protection against reactive oxygen and nitrogen species-induced cell injury. *FEBS letters* 579(14), 3029-3036.

Zhu, Y., Zhang, J., Zeng, Y., 2012. Overview of tyrosine hydroxylase in Parkinson's disease. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)* 11(4), 350-358.